As the world's biggest biotech hub, funding for early-stage startups has long been the lifeblood of Boston's life sciences industry. But the latest figures make for concerning reading—with average seed funding secured by a preclinical start-up plunging 40% over the past year.
In fact, the average seed round for a Massachusetts-based biotech in the first six months of 2026 was just $4.65 million, down from $7.65 million for the same period in 2025, according to the most recent industry snapshot from trade group MassBio. READ MORE
Quisque iaculis facilisis lacinia. Mauris euismod pellentesque tellus sit amet mollis.